CD30-Targeted CAR T Cells Show Promise in Pretreated Hodgkin Lymphoma

Lymphoma
01/08/2020

Cancer Discov. 2020 Jul 31. doi: 10.1158/2159-8290.CD-RW2020-111. Online ahead of print.

ABSTRACT

CD30-directed CAR T cells were safe and produced a 62% overall response rate in Hodgkin lymphoma.